Focused Cryo, Inc — SEC Form D Filing

Focused Cryo, Inc filed an SEC Form D on April 23, 2026, reporting $8.87M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
April 23, 2026
Amount reported
$8.87M
Round stage
Seed
Industry
Health Care
Website
https://www.focusedcryo.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: GEORGIA

Problem

Interventional specialists need to target tumors or nerves precisely to minimize collateral damage, and current approaches may not offer real-time feedback to optimize procedure safety and outcomes.

Solution

Focused Cryo, Inc. offers an FDA 510(k) cleared cryoablation platform with dual-mode freeze control and real-time temperature feedback, enabling adjustable, targeted cryotherapy during surgical procedures to optimize safety and outcomes.

Verdict

Investors said yes to Focused Cryo because the technology promised precise tumor targeting with real-time feedback, not merely because it operated in an advanced surgical niche. They implicitly bet on the assumption that better control during procedures would lead to improved patient outcomes, which is a significant value driver in healthcare. However, limited upside exists as this narrative faces substantial hurdles in differentiating from established players, with risks of becoming just another tool in an overcrowded market.

Source: SEC EDGAR Form D filing